Patents Issued in August 2, 2018
  • TABLET
    Publication number: 20180214460
    Abstract: The present invention provides a tablet showing high stability of the active ingredients (potassium-competitive acid blocker and acetylsalicylic acid) and stably and rapidly expressing the pharmacological effects of the active ingredients after administration. The present invention provides a tablet containing an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains a potassium-competitive acid blocker free of enteric coating.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Inventors: Arisa Maeda, Yuichi Sugiyama, Yoshihiro Uchiyama
  • PHOSPHOPANTETHEINE COMPOUNDS ALONE OR IN COMBINATION WITH HMG-COA REDUCTASE INHIBITORS FOR LOWERING SERUM CHOLESTEROL AND SERUM TRIGLICERIDES
    Publication number: 20180214461
    Abstract: The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.
    Type: Application
    Filed: December 23, 2015
    Publication date: August 2, 2018
    Inventors: Gregor KOSEC, Stefan FUJS, Hrvoje PETKOVIC, Oda Cornelia Maria SIBON, Balaji SRINIVASAN
  • BLOOD-BRAIN-BARRIER PERMEABILITY MODULATORS AND USES THEREOF
    Publication number: 20180214462
    Abstract: Provided are compositions which include N-methyl-d-aspartate receptor (NMDA-R) antagonists. Moreover, provided are methods for reducing the permeability of the blood-brain-barrier, in a patient, by administering to the patient, a composition which includes N-methyl-d-aspartate receptor (NMDA-R) antagonists.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 2, 2018
    Inventors: Alon FRIEDMAN, Yehuda VAZANA
  • USE OF PHYTIC ACID OR THE SALTS THEREOF, ALONE OR COMBINED WITH B6 VITAMERS, FOR PREVENTING THE FORMATION OF ADVANCED GLYCATION END-PRODUCT
    Publication number: 20180214463
    Abstract: The invention relates to the use of phytate or any of the salts thereof for preventing the formation of advanced glycation end-products (AGE), toxic products that are produced in pathologies such as diabetes, either alone or combined with B6 vitamins such as pyridoxamine and forming part of a medicament or a pharmaceutical composition produced so as to be administered via oral, rectal, subcutaneous, intra-arterial, intramuscular, intraspinal, intracranial, intravenous or inhalation routes.
    Type: Application
    Filed: July 8, 2016
    Publication date: August 2, 2018
    Inventors: Félix GRASES FREIXEDAS, Antonia COSTA BAUZÁ, Miguel ADROVER ESTELRICH, Francisco BERGA MONTANER, Pilar SANCHÍS CORTÉS, Luis MASMIQUEL COMAS, Rosmeri RIVERA IROGOIN, Regina FORTUNY MARQUÉS
  • METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES
    Publication number: 20180214464
    Abstract: The present invention relates to compounds and methods for treating retroviral infections and/or Hepatitis B viral infections. Some compounds of the invention are described by Formula I: or a stereoisomer, a diastereomer, an enantiomer or racemate thereof.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventor: Ernest Randall LANIER
  • THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES
    Publication number: 20180214465
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
  • USE OF GINSENOSIDE M1 FOR TREATING IGA NEPHROPATHY
    Publication number: 20180214466
    Abstract: The present invention provides a method of treating a subject afflicted with IgA nephropathy (IgAN) comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.
    Type: Application
    Filed: November 3, 2015
    Publication date: August 2, 2018
    Inventor: SHEAU-LONG LEE
  • GLP-1 SECRETAGOGUE
    Publication number: 20180214467
    Abstract: An object of the present invention is to provide a GLP-1 secretagogue which is an incretin hormone-related drug relatively inexpensive, excellent in safety, and capable of promoting GLP-1 secretion without containing sucrose as an essential constituent. The object is achieved by a GLP-1 secretagogue characterized by containing D-psicose as an active ingredient.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 2, 2018
    Applicants: EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITY, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Matsutani Chemical Industry Co., Ltd.
    Inventors: Toshihiko YADA, Yusaku IWASAKI, Hiroshi HARA, Tohru HIRA, Yuka KISHIMOTO, Machiko MINAMI
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20180214468
    Abstract: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Inventors: Uli Christian BROEDL, Maximilian von EYNATTEN, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd Roland LUIPPOLD
  • ANTICANCER COMPOSITION AND USE THEREOF
    Publication number: 20180214469
    Abstract: A composition for inhibiting a liver tumor in an organism is disclosed. The composition includes an activator being 1,2,3,4,6-penta-O-galloyl-Beta-D-glucopyranoside (PGG), wherein PGG is extracted from at least one of Paeonia lactiflora Pall. and Galla Chinesis.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 2, 2018
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yi-Ming Chen, Chia-Hung Yen, Chung-Kuang Lu
  • NEW EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA
    Publication number: 20180214470
    Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 2, 2018
    Applicants: MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Yoshiaki TAKAHASHI, Eijiro UMEMURA, Takashi IDA, Masayuki IGARASHI
  • COMPOSITION FOR PREVENTING AND TREATING OSTEOPOROSIS, COMPRISING DIHYDROPHASEIC ACID 3-O-B-D-GLUCOPYRANOSIDE ISOLATED FROM LYCIUM ROOT BARK EXTRACTS
    Publication number: 20180214471
    Abstract: The present invention relates to a compound of dihydrophaseic acid 3?-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast.
    Type: Application
    Filed: March 2, 2016
    Publication date: August 2, 2018
    Applicants: DONG WOO DANG CO., LTD, Ajou University Industry-Academic Cooperation Foundation
    Inventors: Dam Heo, Seon Yong Jeong, Eun-guk Park, Moon-chang Kim, Ji Won Lee, Jeong Hyun Kim
  • CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
    Publication number: 20180214472
    Abstract: The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one antifungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA)m-X-(L)n; (ii) [(AFA)m?-X]p-L; (iii) AFA-[X-(L)n?]q; or (iv) (AFA)m?-X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m? is 1 to 10; p is 1 to 10; n? is 1 to 10; and q is 1 to 10, provided that q? and n are not both 1; and m? is 1 to 10. The invention also provides nonaparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.
    Type: Application
    Filed: January 23, 2018
    Publication date: August 2, 2018
    Applicant: VYOME BIOSCIENCES, PVT. LTD.
    Inventors: Abhijit S. Bapat, Gauthami Mahesh, Rajesh S. Gokhale, Sayali S. Shah, Shiladitya Sengupta, Sudhanand Prasad, Sumana Ghosh, Suresh R. Chawrai, Nidhi Arora, D. Sreedhar Reddy, Mallika Mishra, Kirti Bajaj
  • COMPOSITIONS AND METHODS RELATED TO CHARACTERIZING PROVIRAL RESERVOIRS
    Publication number: 20180214473
    Abstract: In some aspects, the invention relates to methods for determining the proportion of intact, hypermutated, deleted, and/or defective proviruses in a sample of nucleic acids, e.g., a sample obtained from a subject. The subject may be a human subject. The virus may be HIV.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 2, 2018
    Inventors: Katherine Bruner, Robert Siliciano
  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20180214474
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.
    Type: Application
    Filed: November 27, 2017
    Publication date: August 2, 2018
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • microRNAS FOR THE TREATMENT OF HEART DISEASES
    Publication number: 20180214475
    Abstract: The invention relates to the field of molecular biology and medicine, more specifically the invention is directed towards the treatment, delay and amelioration of heart diseases. More in particular, microRNAs are provided that induce cardiac regeneration by inducing cell cycle proliferation of cardiomyocytes, thereby treating or ameliorating heart diseases associated with a loss of cardiomyocytes or cardiomyocyte function. Such diseases include myocardial infarction, cardiomyopathy of ischemic or non-ischemic origin, myocarditis and heart failure. More in particular, the invention relates to a composition comprising a microRNA selected from the group consisting of microRNA 106b, microRNA 93 or microRNA 25 and the complements thereof, for use in the treatment, prevention, delay or amelioration of a heart disease.
    Type: Application
    Filed: August 18, 2016
    Publication date: August 2, 2018
    Inventors: Leon Johannes De Windt, Ellen Dirkx, Mauro Giacca
  • THROMBIN-RESPONSIVE HYDROGELS AND DEVICES FOR AUTO-ANTICOAGULANT REGULATION
    Publication number: 20180214476
    Abstract: The present disclosure relates to a thrombin-responsive closed-loop patch for prolonged heparin delivery in a feedback-controlled manner. The microneedle-based patch can sense the activated thrombin and subsequently release heparin to prevent coagulation in the blood flow. The patch can be transcutaneously inserted into skin without drug leaking and can sustainably regulate blood coagulation in response to thrombin.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 2, 2018
    Inventors: Zhen Gu, Jicheng Yu, Yuqi Zhang, Caterina Gallippi
  • GRANULAR COMPOSITION FOR ORAL ADMINISTRATION
    Publication number: 20180214477
    Abstract: The present invention relates to a granular composition for oral suspension characterized by the presence of an insoluble resin and a silica gel.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Inventors: Federico STROPPOLO, Gabriele GRANATA
  • POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION
    Publication number: 20180214478
    Abstract: Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 2, 2018
    Applicant: University of British Columbia
    Inventors: Jayachandran N. Kizhakkedathu, Rajesh A. Shenoi, Cedric J. Carter, Donald E. Brooks
  • MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA
    Publication number: 20180214479
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Application
    Filed: January 23, 2018
    Publication date: August 2, 2018
    Inventors: Donald Jeffrey KEYSER, Alvaro F. GUILLEM
  • PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME
    Publication number: 20180214480
    Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
    Type: Application
    Filed: September 8, 2017
    Publication date: August 2, 2018
    Inventors: Keith CHAN, Winston TOWN, David W.K. KWOK, Nikolay Mintchev STOYNOV
  • READY TO USE SURFACE DISINFECTANT
    Publication number: 20180214481
    Abstract: This invention relates generally to improved chemical formulations and methods of use that provide for the disinfection of microorganisms and biological contaminants as well as the chemical neutralization of toxic materials (toxants) present on selected objects and surfaces. The invention relates more specifically to accelerated hydrogen peroxide based formulations having a secondary biocidal agent present and which demonstrate both desirous enhanced long term storage stability as well as efficacy of action at time of use without requiring the mixing or combination of the separated components immediate prior to use.
    Type: Application
    Filed: January 30, 2017
    Publication date: August 2, 2018
    Applicant: SPECTRA SHIELD TECHNOLOGIES, LLC
    Inventor: TUCKER D. MAURER
  • METHOD OF ENABLING MUSCLE RELAXATION
    Publication number: 20180214482
    Abstract: A method of application to human skin of a water solution of metallic salts at concentrations from 1 to not more than 10 times the normal concentration found in the interstitial cellular space in humans, including the addition of ADP, ATP, to enable muscle relaxation and restore normal muscle function in humans.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 2, 2018
    Applicant: Sense Technology, Inc.
    Inventor: Joseph M. Evans
  • THERAPEUTIC METHODS INVOLVING MODULATING INFLAMMASOME ACTIVATION OF MYELOID-DERIVED SUPPRESSOR CELLS
    Publication number: 20180214483
    Abstract: In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 2, 2018
    Inventors: Bruce R. Blazar, Brent Koehn, Peter J. Murray, Jenny P.Y. Ting, Robert Zeiser, Jeff S. Miller
  • TUMOR LYSATE LOADED PARTICLES
    Publication number: 20180214484
    Abstract: Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 2, 2018
    Applicant: Orbis Health Solutions LLC
    Inventor: Thomas E. Wagner
  • TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES
    Publication number: 20180214485
    Abstract: Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: Philip D. Gregory, Michael C. Holmes, David Paschon, Lei Zhang, Maria Chiara Bonini, Pietro Genovese, Zulma Magnani, Sara Mastaglio, Luigi Naldini
  • BONE MARROW DERIVED CD271 PRECURSOR CELLS FOR CARDIAC REPAIR
    Publication number: 20180214486
    Abstract: Methods for the isolation of CD271+ stem cell populations are important in the prevention or treatment of cardiovascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's body.
    Type: Application
    Filed: September 29, 2017
    Publication date: August 2, 2018
    Inventor: JOSHUA M. HARE
  • PD-L1 EXPRESSING HEMATOPOIETIC STEM CELLS AND USES
    Publication number: 20180214487
    Abstract: Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).
    Type: Application
    Filed: July 20, 2016
    Publication date: August 2, 2018
    Applicant: The Children's Medical Center Corporation
    Inventor: Paolo Fiorina
  • METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATION
    Publication number: 20180214488
    Abstract: The present disclosure relates to the field of hematopoietic stem or progenitor cell transplantation. More specifically, methods, compositions and kits for improving expansion and engraftment of hematopoietic stem or progenitor cells by co-culturing and co-administering with endothelial cells are provided. The methods, compositions and kits are useful for treating various disorders relating to deficiencies in hematopoiesis caused by disease or myeloablative treatments.
    Type: Application
    Filed: July 19, 2016
    Publication date: August 2, 2018
    Inventors: Paul William Finnegan, Claude Geoffrey Davis, Michael Daniel Ginsberg, Daniel Joseph Nolan
  • MESENCHYMAL STEM CELLS WITH ENHANCED EFFICACY IN TREATMENT OF AUTOIMMUNITY PARTICULARLY RHEUMATOID ARTHRITIS
    Publication number: 20180214489
    Abstract: Disclosed herein are protocols, isolation means, and compositions of matter useful for identifying mesenchymal stem cells possessing enhanced clinical activity in treatment of autoimmune conditions, such as rheumatoid arthritis (RA). Additionally, markers associated with said enhanced mesenchymal stem cell activity against autoimmunity can be utilized to identify donors whose mesenchymal stem cells possess superior efficacy compared to mesenchymal stem cells from donors who lack said markers associated with said enhanced efficacy in treatment of autoimmunity, such as RA.
    Type: Application
    Filed: January 29, 2018
    Publication date: August 2, 2018
    Inventor: Neil Riordan
  • METHODS OF TREATING LYSOSOMAL STORAGE DISEASES
    Publication number: 20180214490
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for the provision of proteins lacking or deficient in subjects with a lysosomal storage disease and treatment and/or prevention of lysosomal storage diseases.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 2, 2018
    Inventor: Edward J. Rebar
  • COMPOSITIONS AND METHODS FOR EXPANSION OF EMBRYONIC HEMATOPOIETIC STEM CELLS
    Publication number: 20180214491
    Abstract: The present invention relates to methods, kits and compositions for expansion of embryonic hematopoietic stem cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. Also provided herein are methods for expanding embryonic hematopoietic stem cells using kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. The embryonic hematopoietic stem cells expanded using the disclosed kits, compositions and methods include cells derived from an embryo (e.g., aorta-gonad-mesonephros region of the embryo), embryonic stem cells, induced pluripotent stem cells, or reprogrammed cells of other types.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Irwin D. Bernstein, Brandon K. Hadland
  • Repair of Peripheral Nerve Injury
    Publication number: 20180214492
    Abstract: The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury.
    Type: Application
    Filed: January 5, 2018
    Publication date: August 2, 2018
    Inventors: Douglas H. SMITH, Daniel Kacy CULLEN, John A. WOLF
  • Tissue Grafts Composed Of Micronized Placental Tissue And Methods Of Making And Using The Same
    Publication number: 20180214493
    Abstract: Described herein are tissue grafts composed of at least one membrane, where at least one side of the membrane has micronized placental tissue applied it. Also described herein are methods for making and using the tissue grafts.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Applicant: MiMedx Group, Inc.
    Inventors: Thomas J. Koob, John Daniel, Randall Spencer
  • METHOD AND COMPOSITION FOR PREVENTING EGG ALLERGY
    Publication number: 20180214494
    Abstract: The present invention provides an egg allergy prevention method to be carried out with respect to a human infant, including: a first administration period (first administration step) in which to administer, to an infant, heated egg white protein in an amount of 10 mg to 20 mg per day; and a second administration period (second administration step) which is a period after the first administration period and in which to administer, to the infant, the heated egg white protein in an amount of 65 mg to 90 mg per day.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 2, 2018
    Inventors: Yukihiro OHYA, Shigenori KABASHIMA, Osamu NATSUME, Hirohisa SAITO
  • USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS
    Publication number: 20180214495
    Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Ian Antheni MYLES, Sandip K. DATTA
  • COMPOSITIONS COMPRISING BACTERIAL STRAINS
    Publication number: 20180214496
    Abstract: The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.
    Type: Application
    Filed: March 8, 2018
    Publication date: August 2, 2018
    Inventors: Annick BERNALIER-DONADILLE, Laureen CROUZET, Chloe HABOUZIT
  • REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES
    Publication number: 20180214497
    Abstract: This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 2, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Kah-Whye Peng, Stephen James Russell, Camilo Ayala Breton
  • METHOD FOR REGULATING, PREVENTING AND/OR TREATING PULMONARY INJURY
    Publication number: 20180214498
    Abstract: A method for regulating, preventing, and/or treating pulmonary injury, and/or for regulating, preventing, and/or treating pulmonary injury-related diseases is provided. The method comprises administering to a subject in need an effective amount of FU-LING extract, tumulosic acid, dehydrotuniulosic acid, dehydrotrametenolic acid, and/or poricoic acid A.
    Type: Application
    Filed: January 3, 2018
    Publication date: August 2, 2018
    Inventors: Han-Peng Kuo, Ai-Ling Yeh, Chao-Jih Wang
  • COMPOSITIONS FOR ANTITUSSIVE, EXPECTORANT OR ANTI-INFLAMMATION
    Publication number: 20180214499
    Abstract: The present invention provides a composition containing, as active ingredients, Panax ginseng, Adenophora triphylla, Wolfiporia extensa, Rehmannia glutinosa, and Mel for an antitussive, expectorant, or anti-inflammatory action, and a composition for preventing, alleviating, or treating a respiratory disease. The present invention provides a compositions having excellent effects compared with an existing antitussive agent and expectorant agent. The compositions of the present invention are a naturally derived material and has little cytotoxicity, and thus is expected to be safely used as a medicine or food composition having antitussive, expectorant, and anti-inflammatory effects.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 2, 2018
    Inventors: Seong Min KU, Tae Hun KU, Chul Jong JUNG, Yun Young CHO, Jeong Gyun SEO, Nam Oh KIM, Hee Yoon JEONG, Eun Sik CHOI, Hye Ran GONG, Sae Kwang KU
  • BEAUTYBERRY TOTAL GLYCOSIDES EXTRACT AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20180214500
    Abstract: Disclosed is a composition comprising an beautyberry total glycosides extract, and a method of preparation thereof, and the use of the composition thereof in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract thereof is prepared from the leaves of Callicarpa cathayana H.T. Chang or Callicarpa formosana Rolfe, and contains 18% to 45% verbascoside and 15% to 40% Arenarioside.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Inventors: Jingge Liu, Yijun Cheng, Jinguo Cao, Yongliang Zhu, Xiangping Qian
  • Colloidal suspension for the healing of various cancers
    Publication number: 20180214501
    Abstract: The present invention pertains to a herbal formulation with potent antineoplastic properties, in humans and animals. The composition consists of the powdered radix of saussurea lappa and nigella sativa in raw honey colloidal suspension in well-defined ratios. The invention also includes a process for preparing the formulation, by creating a honey based colloidal suspension of the components, nigella sativa and saussurea lappa.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 2, 2018
    Inventor: Shajar Abid
  • FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE
    Publication number: 20180214502
    Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 2, 2018
    Inventors: Christopher Brian LUNDIN, Terry SHIRVANI
  • COMPOSITION FOR WOUND TREATMENT CONTAINING EXTRACT OF STELLERA CHAMAEJASME OR FRACTION THEREOF AND METHOD FOR TREATING WOUND OF SUBJECT
    Publication number: 20180214503
    Abstract: Provided are a composition including Stellera chamaejasme extract for treating wound, a method of treating wound of a subject, a cosmetic composition for wound improving, skin wrinkle improving, or skin anti-aging, and a method of cosmeticizing for wound improving, skin wrinkle improving, or skin anti-aging.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chu Won NHO, Myung Suk KIM, Hee Ju LEE, Kil Choo MOON, Sang Rok OH, Dulamjav BATSUREN
  • HEALTH SUPPLEMENT FOOD FOR PROMOTION OF HAIR GROWTH, MITIGATION AND ALLEVIATION OF HAIR LOSS, REGULATION OF BLOOD GLUCOSE, AND ALLEVIATION AND RELIEF OF GASTRIC DISORDER SYMPTOMS
    Publication number: 20180214504
    Abstract: The present invention relates to a health supplement food. More particularly, the present invention relates to a health supplement food prepared by mixing dried powders, wherein the dried powders include 5 to 15% by weight of black beans, 5 to 15% by weight of black sesame seeds, 5 to 15% by weight of corn, 5 to 15% by weight of adlay, 5 to 15% by weight of sorghum, 5 to 15% by weight of mulberry leaves, 5 to 15% by weight of mulberry fruits, 7 to 20% by weight of Polygonum multiflorum Thunberg, 5 to % by weight of dandelion, 1 to 10% by weight of licorice, 2 to 15% by weight of kelp, and 5 to 15% by weight of cactus based on solid content. The health supplement food may exhibit effects such as promotion of hair growth, alleviation and mitigation of hair loss, regulation of blood glucose, or alleviation and relief of gastric disorder symptoms.
    Type: Application
    Filed: March 11, 2016
    Publication date: August 2, 2018
    Inventor: Kyung Il KIM
  • INFLAMMATION-SUPPRESSING COMPOSITION INCLUDING PEPTIDE
    Publication number: 20180214505
    Abstract: An oligopeptide having a good anti-inflammation effect on microglia has been found, and based on this finding, a composition to be used for suppressing the inflammation of microglia is provided. Inflammation suppression action of a dipeptide has been comprehensively analyzed using the proinflammatory cytokine production of microglia as an indicator. As a result, it has been revealed that an oligopeptide including the sequence LH, DV or MH has a good inflammation suppression effect. The composition containing any of these oligopeptides can provide a composition having the effect of suppressing the excessive inflammatory action of microglia.
    Type: Application
    Filed: May 26, 2016
    Publication date: August 2, 2018
    Applicant: KIRIN KABUSHIKI KAISHA
    Inventors: Yasuhisa ANO, Masahiro KITA
  • COMBINATION ADMINISTRATION OF GNRH ANTAGONISTS
    Publication number: 20180214506
    Abstract: Disclosed herein are methods of administering to a subject a GnRH antagonist with enhanced bioavailability. Also disclosed herein are methods of treating or preventing a disease or condition by administering a GnRH antagonist, and kits comprising the GnRH antagonist.
    Type: Application
    Filed: January 30, 2018
    Publication date: August 2, 2018
    Inventor: Finn LARSEN
  • COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
    Publication number: 20180214507
    Abstract: The invention provides compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists, and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 2, 2018
    Inventors: Ravi Kacker, Mitchell S. Steiner
  • COMPOSITION CONTAINING CYCLIC DIPEPTIDE AND SWEETENING AGENT
    Publication number: 20180214508
    Abstract: Provided a composition excellent in biological safety and capable of enhancing GLP-1 secretion-accelerating effect due to a sweetening agent. The content ratio of the cyclic dipeptide or a salt thereof and a sweetening agent in a composition is controlled to fall within a specified range. Owing to this, GLP-1 secretion-accelerating effect due to the sweetening agent is enhanced.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 2, 2018
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Toshihide SUZUKI, Natsumi HIRAKI
  • USE OF A BACTERIUM ISOLATED FROM THE GENUS PSEUDOALTEROMONAS, CYCLOLIPOPEPTIDES AND USES THEREOF
    Publication number: 20180214509
    Abstract: The present invention relates to an isolated bacterium from the genus Pseudoalteromonas for its use as a probiotic, the use of said strain as a preservative, cyclolipopeptides which may be obtained from this bacterium, a composition comprising at least such a cyclolipopeptide, as well as to their uses.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE DE RENNES 1, UNIVERSITE DE BRETAGNE OCCIDENTALE
    Inventors: Florie DESRIAC, Yannick FLEURY, Patrick LE CHEVALIER, Delphine DESTOUMIEUX, Matthieu SIMON